XML 106 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)
 1 Months Ended 12 Months Ended
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
product_target
$ / shares
Apr. 30, 2020
USD ($)
product_target
$ / shares
shares
Dec. 31, 2021
USD ($)
product_target
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Accounts receivable       $ 6,013,000 $ 5,224,000  
Net pension losses           $ 25,000
Biogen MA, Inc. | Stock Purchase Agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Sale of stock, number of shares issued in transaction (in shares) | shares     24,420,157      
Sale of stock, price per share (in dollars per share) | $ / shares   $ 9.2137 $ 9.2137      
Consideration received from sale of stock   $ 225,000,000 $ 225,000,000      
Agreement restriction expiration period     3 years      
Agreement restriction, ownership percentage (less than)   5.00% 5.00%      
Agreement restriction, percentage of shares held   50.00% 50.00%      
Agreement provision, expiration period     2 years      
Agreement provision, ownership percentage (less than)   5.00% 5.00%      
Collaborative arrangement transaction price     $ 204,600,000      
Sale of stock, excess consideration received on transaction     79,600,000      
Collaboration agreement, equity issued   $ 145,400,000 145,400,000 145,400,000    
Accounts receivable       2,800,000 2,700,000  
Deferred revenue       154,000,000 $ 183,200,000  
Net pension losses       $ 2,900,000    
Biogen MA, Inc. | Collaboration and license agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Proceeds from collaborators $ 125,000,000   125,000,000      
Maximum milestone payment receivable   $ 2,400,000,000 $ 2,400,000,000      
Number of neurological disease gene targets | product_target     12      
Number of additional neurological disease gene targets | product_target     8      
Target selection period     5 years      
Number of product targets selected | product_target   3 3      
Collaborative arrangement, maximum number of product targets to replace | product_target       10    
Collaboration arrangement, commission fee, portion of gross proceeds, value       $ 7,000,000    
Collaborative agreement, percent of initial recognition       2.00% 2.00%  
Contract with customer, asset, after allowance for credit Loss       $ 4,100,000    
Amortization cost       $ 600,000 $ 400,000  
Biogen MA, Inc. | Collaboration and license agreement | Maximum            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Collaboration arrangement, research period     7 years      
Biogen MA, Inc. | Collaboration and license agreement | Pre-approval Milestone            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Maximum milestone payment receivable   $ 925,000,000 $ 925,000,000      
Biogen MA, Inc. | Collaboration and license agreement | Sales-based Milestone            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Maximum milestone payment receivable   $ 1,500,000,000 $ 1,500,000,000